Icatibant "viatris"

Icatibant, the active ingredient in Icatibant viatris, is a bradykinin B2 receptor antagonist presented as a sterile subcutaneous injection solution for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with confirmed HAE diagnosis and can provide rapid symptom relief under medical supervision.

GNH USA supplies Icatibant viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable cold‑chain logistics for biologic products across Europe, Asia and the Americas.

Icatibant is used to target bradykinin‑mediated pathways in hereditary angioedema, providing rapid control of swelling.

- Hereditary angioedema type I: reduces swelling during acute attacks, improving airway safety. - Hereditary angioedema type II: provides rapid symptom control and shortens attack duration. - Hereditary angioedema with normal C1‑INH: offers targeted therapy for patients unresponsive to C1‑INH replacement. - Acute HAE attacks in adults: delivers a subcutaneous dose that quickly alleviates pain and edema.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic response.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema: worsening of swelling in face, lips or airway. - Severe hypotension: sudden drop in blood pressure.

Before using Icatibant, consider the following precautions: - Pregnancy: safety not established; use only if benefit outweighs risk. - Breastfeeding: unknown effects; consider discontinuation. - Renal impairment: use with caution, monitor patient response. - Concomitant ACE inhibitors: increased risk of bradykinin‑mediated angioedema; monitor closely. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines; review the following categories.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin accumulation and increase risk of angioedema. - Estrogen‑containing contraceptives: can exacerbate bradykinin‑mediated swelling.

Moderate Interactions (Monitor Closely): - NSAIDs: may augment inflammatory response, monitor for increased edema. - C1‑INH concentrate: concurrent use may reduce efficacy of Icatibant; assess clinical need. - Other bradykinin antagonists: additive pharmacodynamic effect; adjust therapy as needed.